My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ImmunoGen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022 ↗

March 21, 2022

Upgrades According to B. Riley Securities, the prior rating for BRT Apartments Corp (NYSE:BRT) was changed from Neutral to Buy. BRT Apartments earned $0.41 in the fourth quarter,...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 21, 2022

Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million.

Via Benzinga

Why Are ImmunoGen Shares Trading Lower Today ↗

March 21, 2022

ImmunoGen Inc (NASDAQ: IMGN)

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

March 21, 2022

Welcome back, investor! We're getting right into the thick of it with a look at the biggest pre-market stock movers for Monday!

Via InvestorPlace

28 Stocks Moving in Monday's Pre-Market Session ↗

March 21, 2022

Gainers BitNile Holdings, Inc. (NYSE: NILE) rose 61.1% to $0.90 in pre-market trading. BitNile's TurnOnGreen resumed expansion of its electric vehicle charging network and e-...

Via Benzinga

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision ↗

February 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To...

Via Benzinga

Immunogen: Q4 Earnings Insights ↗

February 25, 2022

Immunogen (NASDAQ:IMGN) reported its Q4 earnings results on Friday, February 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Earnings Scheduled For February 25, 2022 ↗

February 25, 2022

Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •...

Via Benzinga

Earnings Outlook For Immunogen ↗

February 24, 2022

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B ↗

February 15, 2022

ImmunoGen Inc (NASDAQ: IMGN) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY) to grant exclusive rights to research, develop, and...

Via Benzinga

Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer ↗

January 06, 2022

Sutro Biopharma could still find a place for itself in ovarian cancer treatment.

Via Investor's Business Daily

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

61 Biggest Movers From Yesterday ↗

December 02, 2021

Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down...

Via Benzinga

Topics Intellectual Property

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021 ↗

December 01, 2021

Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV

Via Benzinga

50 Stocks Moving In Wednesday's Mid-Day Session ↗

December 01, 2021

Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's...

Via Benzinga

Topics Intellectual Property

The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case ↗

December 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...

Via Benzinga

Topics Intellectual Property

10 Biggest Price Target Changes For Wednesday ↗

December 01, 2021

Morgan Stanley boosted Zscaler, Inc. (NASDAQ: ZS) price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading. Citigroup boosted Applied...

Via Benzinga

A Peek Into The Markets: US Stock Futures Higher Ahead Of ADP, Manufacturing Data ↗

December 01, 2021

Pre-open movers U.S. stock futures traded higher in early pre-market trade after recording gains in the previous session. Investors are awaiting earnings results from G-...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 30, 2021

Gainers Cumberland (NASDAQ:CPIX) stock...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 30, 2021

Gainers Lannett (NYSE:LCI) shares rose 11.61...

Via Benzinga

52 Biggest Movers From Yesterday ↗

December 01, 2021

Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...

Via Benzinga

Why ImmunoGen Stock Soared Today ↗

November 30, 2021

The cancer-fighting specialist's new antibody treatment could be a gamechanger.

Via The Motley Fool

Mid-Afternoon Market Update: Dow Dips 500 Points; ImmunoGen Shares Spike Higher ↗

November 30, 2021

Toward the end of trading Tuesday, the Dow traded down 1.44% to 34,628.69 while the NASDAQ fell 1.34% to 15,571.16. The S&P also fell, dropping 1.36% to 4,592.03. The U.S. has...

Via Benzinga

Topics Stocks

These 2 Nasdaq Biotechs Are Bucking the Market Downtrend ↗

November 30, 2021

Wall Street is having a bad day, but shareholders in these companies are celebrating.

Via The Motley Fool

Topics Stocks

Mid-Day Market Update: Barnes & Noble Education Drops Following Q2 Results; Cumberland Pharmaceuticals Shares Jump ↗

November 30, 2021

Midway through trading Tuesday, the Dow traded down 0.88% to 34,827.81 while the NASDAQ fell 0.78% to 15,659.31. The S&P also fell, dropping 0.3832% to 4,616.53. The U....

Via Benzinga

Topics Stocks

35 Stocks Moving In Tuesday's Mid-Day Session ↗

November 30, 2021

Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an...

Via Benzinga

ImmunoGen Shares Rally After Ovarian Cancer Trial Meets Primary Endpoint Goal ↗

November 30, 2021

ImmunoGen Inc (NASDAQ: IMGN) shares have gained more than 30% during premarket trading in reaction to positive topline data from the SORAYA trial of mirvetuximab...

Via Benzinga

The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout ↗

November 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 30, 2021

Gainers Cumberland (NASDAQ:CPIX) shares rose 91.81% to $4.22 during Tuesday's pre-market session. The company's market cap stands at $62.4 million. First Wave...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.